Abstract 15542: Impact of Treatment with Apixaban and Aspirin in Patients with Atrial Fibrillation in Relation to the CHADS2 and CHA2DS2-VASc Scores: the AVERROES Study
Background - In the AVERROES (Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) trial, 5598 patients with atrial fibrillation (AF) for whom vitamin K antagonist therapy was unsuitable were randomised to treatment with aspirin (81-324mg daily) or the oral Factor Xa inhibitor, apixaban (5 mg twice daily). The CHADS2 and CHA2DS2-VASc scores are used for stroke risk stratification in atrial fibrillation (AF).
Methods - We assessed the effect of treatment with aspirin and apixaban on stroke and systemic embolism, in relation to the CHADS2 and CHA2DS2-VASc scores in the AVERROES population
Results - There was no significant heterogeneity for the treatment effect for apixaban with respect to stroke risk strata, as assessed by the CHADS2 and CHA2DS2-VASc scores.
Conclusion - In a AF population with one or more stroke risk factors, apixaban was superior to aspirin for the prevention of stroke and thromboembolism, irrespective of stroke risk strata.
- © 2011 by American Heart Association, Inc.